Abstract
Abstract Abstract #1137 Aim: To investigate the management of bone health in postmenopausal women with early breast cancer (BCA) scheduled to receive anastrozole.
 Methods: Postmenopausal women with hormone receptor-positive early BCA were assigned to 1 of 3 strata depending on their pre-existing risk of fragility fracture. Patients (pts) with a bone mineral density (BMD) T-score <-2.0 for either spine or hip, or those pts deemed by the investigator to be at increased risk of fracture, were designated higher-risk (H) for fracture and received anastrozole 1 mg/day plus risedronate 35 mg/week orally. Moderate-risk (M) pts (T-score <-1.0 for spine or hip but ≥-2.0 at both sites) were randomized in a double-blind manner to receive anastrozole plus risedronate (A+R) or anastrozole plus placebo (A+P). Pts with T-scores ≥-1.0 at both spine and hip were designated lower-risk (L) and received anastrozole alone. All pts received calcium and vitamin D. Lumbar spine and total hip BMD were assessed at baseline, 12, and 24 months.
 Results: BMD changes at 24 months are shown in the table. In M, a significant difference in favor of the A+R group compared with the A+P group was seen for both lumbar spine and total hip (both p<0.0001). In H, risedronate therapy was associated with increases in BMD at the lumbar spine (p=0.0006) and total hip (p=0.01). In L, no bisphosphonate therapy was associated with a significant decrease in BMD at the lumbar spine (p=0.01) but not at the total hip. Pts who withdrew did not appear to have an impact on the results. The safety and tolerability profile of anastrozole was similar to that already established and was not significantly altered by the addition of risedronate.
 Conclusions: In postmenopausal women at risk for fragility fracture receiving adjuvant anastrozole for BCA, the addition of risedronate at doses established for preventing and treating osteoporosis resulted in favorable affects in BMD over 24 months.
 
 Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1137.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
